LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; CAD, coronary artery disease; PAD, peripheral artery disease; OSA, obstructive sleep apnoea; MI, myocardial infarction; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose co-transporter 2 inhibitor; CPAP, continuous positive airway pressure therapy; ICD, implantable cardioverter-defibrillator; and CRT, cardiac resynchronization therapy. This evidence concerns the gene NR3C2 and peripheral arterial disease.